Propecia (Merck) AI Market Strategy Report - Hair Loss Treatments

Answer Capsule

Propecia (Merck) shows minimal AI recommendation presence in the Hair Loss Treatments category for June 2026, appearing in only 1.0% of all observations across six AI platforms. The brand captures a monthly AI Authority Value of $1,382, representing a negligible share of the $53.2M category opportunity. Propecia carries a net sentiment score of 0.36, indicating mostly neutral-to-slightly-positive framing on the rare occasions it appears. The clearest weakness is near-zero recommendation coverage across every high-intent cluster, and the clearest opportunity is building a citation architecture that supports clinical recommendation eligibility before competitors extend their lead further.

Who This Report Is For

This report is for Merck brand strategists, digital marketing leaders, and category analysts evaluating how AI discovery platforms are shaping consumer shortlists for prescription hair loss treatments.

Report Card

• Report type: AI Company Market Strategy Report
• Target company: Propecia (Merck)
• Category / market studied: Hair Loss Treatments
• Reporting month: June 2026
• AI platforms tracked: ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity
• Public high-intent clusters: 3 (Best Telehealth and Online Prescription Services, Telehealth Platform Comparisons, Telehealth and Online Prescription Pricing)
• AI observations analyzed: 1,102
• Competitors tracked: 10 (Nutrafol, Rogaine, Keeps, Hims, Happy Head, Bosley, HairClub, Ro (Roman), Folexin, Propecia (Merck))

Executive Summary

Propecia (Merck) registers minimal AI recommendation presence in the Hair Loss Treatments category for June 2026. The brand appears in only 11 of 1,102 observations across six AI platforms, producing a raw mention presence rate of 1.0%. Of those 11 appearances, 5 are positive, 5 are neutral, and 1 is negative. The brand receives only 1 valid recommendation across all platforms, yielding a valid recommendation coverage rate of 0.45%.

The monthly AI Authority Value for Propecia is $1,382. This represents a negligible fraction of the $53.2M total category opportunity and places Propecia at the bottom of the competitive universe alongside Folexin and HairClub. The brand has no rank-one recommendations and only one top-three recommendation across all observations.

Propecia's strongest cluster is Telehealth Platform Comparisons (C02), where it appears in 5 observations and receives its only valid recommendation. In the highest-intent pricing cluster, the brand appears with positive framing but generates no recommendation credit. On Google AI Overviews, Propecia shows its strongest platform signal with 5 appearances and 4 positive mentions, though this presence does not convert into recommendation power.

The distance between brand recognition and recommendation eligibility is severe. Propecia is a clinically established prescription medication with decades of research behind it. Yet the benchmark shows AI systems are not advancing it as a treatment option. This is not a simple visibility problem. It is a recommendation architecture problem, and the evidence suggests the gap is structural rather than incidental.

The category context makes the gap more significant. Category leader Nutrafol captures $3.9M in monthly AI Authority Value with a valid recommendation coverage rate of 24.9%. Keeps captures $3.2M. Rogaine captures $2.5M. Propecia's $1,382 represents less than 0.03% of Nutrafol's captured value. Every competitor in the tracked universe outperforms Propecia on recommendation coverage.

What Propecia (Merck) Is Winning

Propecia's net sentiment score of 0.36 sits above Bosley (0.11) and HairClub (0.03). When the brand does appear in AI responses, the framing trends positive rather than neutral or cautionary. This matters because it indicates that the brand is not generating negative signals that would actively suppress recommendation eligibility.

On Google AI Overviews, Propecia achieves its strongest platform signal, with 5 appearances and 4 positive mentions. This is the one platform where the brand shows consistent positive framing, suggesting that the evidence layer AI Overviews draws on contains clinically credible source material for Propecia.

In the Telehealth Platform Comparisons cluster (C02), Propecia receives 5 observations and its only valid recommendation. This is a narrow but real pocket of recommendation credit. It shows that AI systems recognize Propecia as a relevant option in structured evaluation contexts, even if that recognition rarely converts.

In the pricing cluster (C03), the brand carries a net sentiment score of 0.75, its highest cluster-level sentiment reading. When Propecia appears at the decision moment, the framing is positive. The sample size is too small to carry analytical weight on its own, but the directional signal is not negative.

Where Propecia (Merck) Has the Clearest AI Visibility Gaps

The most critical gap is the near-complete absence of recommendation conversion. Propecia appears in 11 observations but receives only 1 valid recommendation. The 0.45% valid recommendation coverage rate means AI systems are retrieving the brand but almost never advancing it as a treatment option for consumers who are ready to decide.

Platform coverage is thin across most of the tracked universe. Propecia shows zero presence on ChatGPT, the platform that reaches the broadest general consumer audience for health and treatment queries. On Copilot and Gemini, the brand appears in only 1 observation each. Google AI Mode records only 1 observation. Perplexity records 2. The concentration of all meaningful presence on Google AI Overviews suggests the brand's public evidence layer is not structured in a way that multiple AI systems can retrieve and cite.

In the consideration cluster (C01), which captures consumers beginning to evaluate their options, Propecia appears in only 2 observations, records 1 positive mention, and receives no recommendations. This is the entry point of the buyer journey. Absence here means consumers forming their shortlists are not encountering Propecia as an option worth considering.

Competitor displacement is consistent across the dataset. Nutrafol, Keeps, Hims, and Rogaine each hold valid recommendation coverage rates well above Propecia's. These brands are not just more visible. They are being recommended at scale when consumers ask for hair loss treatment options. Propecia is being retrieved occasionally but is not making shortlists.

The brand's average recommended rank of 2.0 is based on a single data point and cannot be interpreted as a meaningful competitive signal. The metric flags eligibility in isolation, not competitive standing.

Biggest Opportunity

Build a clinical citation architecture that supports recommendation eligibility. Propecia has decades of clinical evidence, FDA-approval history, and documented efficacy that AI systems could cite in treatment comparison responses. The benchmark evidence suggests that evidence is not currently structured or distributed in a way that AI systems can retrieve and use to justify a recommendation. Developing structured, retrievable source material that positions Propecia as a clinically validated prescription option in evaluation and decision-stage prompts is the highest-leverage action available. This means comparison pages, clinical summary content, dermatologist review signals, and pricing and access information presented in a format that AI systems can extract and cite.

Prompt Evidence

Google AI Overviews / Telehealth Platform Comparisons Prompt: "Compare hair loss treatment options" Result: Propecia appears in the response but is not ranked or shortlisted as a top option, receiving mention-level presence without recommendation credit.

Gemini / Best Telehealth and Online Prescription Services Prompt: "What is the best treatment for hair loss?" Result: Propecia is mentioned neutrally without being advanced as a recommendation, indicating retrieval without recommendation conversion.

Google AI Overviews / Telehealth and Online Prescription Pricing Prompt: "How much does hair loss treatment cost?" Result: Propecia appears with positive framing but is not included in the ranked shortlist, suggesting that pricing-layer source material is insufficient to earn recommendation credit.

Copilot / Telehealth Platform Comparisons Prompt: "Which hair loss treatments are worth considering?" Result: Propecia appears but receives negative framing, the only negative mention in the dataset, suggesting that Copilot's source layer is surfacing cautionary or side-effect-weighted content rather than clinical recommendation content.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Map Propecia's current mention and recommendation profile across all six platforms to identify the specific prompts where the brand is retrieved but not recommended, and surface the source types AI systems are currently drawing on.

Phase 2: Recommendation Readiness Plan Identify the citation and source gaps preventing AI systems from advancing Propecia as a recommended option, with particular focus on clinical comparison framing, dermatologist review content, and access and pricing documentation.

Phase 3: Owned Answer Layer Buildout Develop structured content that positions Propecia as a clinically validated prescription option, including treatment comparison pages, clinical evidence summaries, and structured pricing and access information that AI systems can extract cleanly.

Phase 4: Citation and Authority Layer Development Build retrievable source material across editorial, clinical, and comparison channels so that AI systems evaluating hair loss treatment options have sufficient evidence to cite Propecia as a recommendation-eligible option.

Phase 5: Monthly AI Visibility and Recommendation Tracking Monitor Propecia's recommendation coverage, rank position, sentiment, and platform presence monthly to measure progress against baseline and adjust strategy as model behavior shifts.

Why This Matters

AI platforms are becoming the primary discovery mechanism for consumers evaluating hair loss treatments. When a consumer asks which treatment is worth trying or which prescription option is most effective, the brands that appear in the shortlist capture the buying moment. Propecia is being retrieved by AI systems but is not being recommended. This means the brand is visible enough to be referenced but not sufficiently supported by the source layer AI systems need to justify a recommendation.

The gap between clinical reputation and AI recommendation eligibility is the central commercial challenge for Propecia in this dataset. The brand carries the clinical evidence to support recommendations. That evidence is not currently structured in a way AI systems can retrieve and cite at the decision moment. Without a deliberate citation architecture, Propecia will continue to appear occasionally in AI responses as a contextual reference while competitors with stronger public evidence layers capture the recommendations and the buyers.

Core Metrics

• Mentions: 11
• Valid recommendations: 1
• Top 3 recommendation count: 1
• Rank #1 recommendation count: 0
• Average recommended rank: 2.0 (based on 1 data point; interpret with caution)
• Positive mentions: 5
• Neutral mentions: 5
• Negative mentions: 1
• Raw mention presence rate: 1.0%
• Valid recommendation coverage: 0.45%
• Top 3 recommendation rate: 0.09%
• Rank #1 recommendation rate: 0.0%
• Strongest cluster by recommendation behavior: Telehealth Platform Comparisons (C02)
• Strongest platform by recommendation behavior: Google AI Overviews

Note: The Core Metrics section reflects a discrepancy present in the source packet. The Executive Summary references 5 valid recommendations while the structured metrics report 1 valid recommendation. This report uses the structured metric of 1 valid recommendation as the controlling figure. The discrepancy has been flagged for source-level review.

Sentiment Score

Sentiment Score = (positive mentions x 1 + neutral mentions x 0 + negative mentions x -1) / total mentions

Sentiment Score = (5 x 1 + 5 x 0 + 1 x -1) / 11 = 4 / 11 = 0.36

Propecia's framing is slightly positive when it appears, but the sample of 11 mentions is too small to carry statistical weight. This score should be read as a directional signal, not a stable measure of brand health.

The broader point is methodological. Unclassified mention counts are misleading because they treat a neutral reference and a positive recommendation as equivalent signals. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal outcomes. Counting all appearances as wins produces a flattering but inaccurate picture of recommendation-stage performance. Classified sentiment is required before any meaningful interpretation of AI visibility is possible.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Propecia (Merck) in the Hair Loss Treatments category, produced using the LLM Authority Index dataset for June 2026. It is not a client implementation case study and does not represent CiteWorks Studio campaign outcomes.
2. The reporting window is June 2026. Data reflects AI system behavior during that period and should be interpreted as a point-in-time benchmark.
3. Six AI platforms were tracked: ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, and Perplexity.
4. A total of 1,102 observations were analyzed across three public high-intent prompt clusters. The full LLM Authority Index report for this category covers 10 clusters.
5. The competitor universe includes 10 brands: Nutrafol, Rogaine, Keeps, Hims, Happy Head, Bosley, HairClub, Ro (Roman), Folexin, and Propecia (Merck).
6. Three public high-intent clusters are covered in this report: Best Telehealth and Online Prescription Services (consideration stage), Telehealth Platform Comparisons (evaluation stage), and Telehealth and Online Prescription Pricing (decision stage).
7. Stage 0 refers to the raw observation layer where AI-generated responses are captured before classification into mentions, recommendations, and sentiment categories.
8. A mention is defined as any appearance of the brand in an AI-generated response, regardless of sentiment, rank, or recommendation status.
9. A valid recommendation is a positive, shortlist-quality appearance that earns recommendation credit. Visibility is not equivalent to recommendation credit. Neutral references, cautionary mentions, and contextual appearances are not counted as valid recommendations.
10. Monthly AI Authority Value is a modeled benchmark value assigned to positive valid top-three recommendations. It is not revenue, pipeline, or booked demand.
11. A data discrepancy between the narrative summary and structured metrics for Propecia's valid recommendation count was identified during production. The structured metric of 1 valid recommendation is used as the controlling figure throughout this report.
12. Limitations: AI outputs change as models update and source material shifts. Modeled values are estimates. This report covers 3 of 10 tracked clusters in the public version. Propecia's observation count of 11 is small, and individual metric values should be interpreted with caution rather than as statistically stable measures.

See How AI Is Recommending Your Brand

The public benchmark establishes the category shape. A company-specific analysis maps which prompts Propecia wins or loses, which AI platforms are under-recognizing the brand, which source layers are shaping current recommendations, and where targeted corrections to the prompt, page, and citation layers would improve shortlist eligibility. Contact CiteWorks Studio for an AI Visibility Audit that shows where your brand stands at the recommendation moment and what competitors are capturing instead.